首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment
【24h】

Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment

机译:Fc受体样5通过SHP-1酪氨酸磷酸酶募集抑制B细胞活化

获取原文
获取原文并翻译 | 示例
       

摘要

The Fc receptor-like protein 5 (FCRL5) on B cells has both an immunoreceptor tyrosine-based activation motif (ITAM)-like sequence and two consensus immunoreceptor tyrosine-based inhibitory motifs (ITIM) in its cytoplasmic region. To evaluate its signaling potential, we expressed constructs for chimeric molecules composed of the cytoplasmic region of FCRL5 and the extracellular and transmembrane regions of the IgG Fc receptor FcγRIIB in a B cell line lacking an endogenous Fc receptor. Coligation of this fusion protein with the B cell receptor (BCR) inhibited BCR-mediated calcium mobilization, intracellular tyrosine phosphorylation, and Erk kinase activation. Our mutational analysis indicated that, whereas tyrosines in both the inhibitory and activation motifs are phosphorylated after ligation, only those in ITIMs influence BCR-mediated signaling. This FCRL5 inhibitory effect was mediated through dual ITIM recruitment of the SH2-containing protein tyrosine phosphatase, SHP-1, which in turn dephosphorylates the ITAM-based tyrosines in BCR Igα/Igβ heterodimers. An FCRL5 inhibitory effect on BCR signaling was likewise demonstrable for primary B cells. Although its ligand is presently unknown, we conclude that FCRL5 has the functional potential to serve as an inhibitory coreceptor on mature B cells in humans.
机译:B细胞上的Fc受体样蛋白5(FCRL5)在其细胞质区域中既具有基于免疫受体酪氨酸的激活基序(ITAM)样序列,又具有两个基于共有免疫受体酪氨酸的抑制基序(ITIM)。为了评估其信号传导潜力,我们在缺乏内源性Fc受体的B细胞系中表达了由FCRL5的胞质区域以及IgG Fc受体FcγRIIB的胞外和跨膜区域组成的嵌合分子的构建体。该融合蛋白与B细胞受体(BCR)的结合抑制了BCR介导的钙动员,细胞内酪氨酸磷酸化和Erk激酶激活。我们的突变分析表明,虽然抑制和激活基序中的酪氨酸在连接后都被磷酸化,但只有ITIM中的酪氨酸会影响BCR介导的信号传导。此FCRL5抑制作用是通过ITIM募集含SH2的蛋白酪氨酸磷酸酶SHP-1的双重介导的,后者又使BCRIgα/Igβ异二聚体中基于ITAM的酪氨酸脱磷酸化。对于原代B细胞同样显示出对BCR信号传导的FCRL5抑制作用。尽管目前尚不清楚其配体,但我们得出的结论是,FCRL5具有在人的成熟B细胞上充当抑制性共受体的功能潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号